Cargando…

Targeting NRF2 for the Treatment of Friedreich’s Ataxia: A Comparison among Drugs

NRF2 (Nuclear factor Erythroid 2-related Factor 2) signaling is impaired in Friedreich’s Ataxia (FRDA), an autosomal recessive disease characterized by progressive nervous system damage and degeneration of nerve fibers in the spinal cord and peripheral nerves. The loss of frataxin in patients result...

Descripción completa

Detalles Bibliográficos
Autores principales: Petrillo, Sara, D’Amico, Jessica, La Rosa, Piergiorgio, Bertini, Enrico Silvio, Piemonte, Fiorella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6829337/
https://www.ncbi.nlm.nih.gov/pubmed/31640150
http://dx.doi.org/10.3390/ijms20205211
_version_ 1783465531321352192
author Petrillo, Sara
D’Amico, Jessica
La Rosa, Piergiorgio
Bertini, Enrico Silvio
Piemonte, Fiorella
author_facet Petrillo, Sara
D’Amico, Jessica
La Rosa, Piergiorgio
Bertini, Enrico Silvio
Piemonte, Fiorella
author_sort Petrillo, Sara
collection PubMed
description NRF2 (Nuclear factor Erythroid 2-related Factor 2) signaling is impaired in Friedreich’s Ataxia (FRDA), an autosomal recessive disease characterized by progressive nervous system damage and degeneration of nerve fibers in the spinal cord and peripheral nerves. The loss of frataxin in patients results in iron sulfur cluster deficiency and iron accumulation in the mitochondria, making FRDA a fatal and debilitating condition. There are no currently approved therapies for the treatment of FRDA and molecules able to activate NRF2 have the potential to induce clinical benefits in patients. In this study, we compared the efficacy of six redox-active drugs, some already adopted in clinical trials, targeting NRF2 activation and frataxin expression in fibroblasts obtained from skin biopsies of FRDA patients. All of these drugs consistently increased NRF2 expression, but differential profiles of NRF2 downstream genes were activated. The Sulforaphane and N-acetylcysteine were particularly effective on genes involved in preventing inflammation and maintaining glutathione homeostasis, the dimethyl fumarate, omaxevolone, and EPI-743 in counteracting toxic products accumulation, the idebenone in mitochondrial protection. This study may contribute to develop synergic therapies, based on a combination of treatment molecules.
format Online
Article
Text
id pubmed-6829337
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-68293372019-11-18 Targeting NRF2 for the Treatment of Friedreich’s Ataxia: A Comparison among Drugs Petrillo, Sara D’Amico, Jessica La Rosa, Piergiorgio Bertini, Enrico Silvio Piemonte, Fiorella Int J Mol Sci Article NRF2 (Nuclear factor Erythroid 2-related Factor 2) signaling is impaired in Friedreich’s Ataxia (FRDA), an autosomal recessive disease characterized by progressive nervous system damage and degeneration of nerve fibers in the spinal cord and peripheral nerves. The loss of frataxin in patients results in iron sulfur cluster deficiency and iron accumulation in the mitochondria, making FRDA a fatal and debilitating condition. There are no currently approved therapies for the treatment of FRDA and molecules able to activate NRF2 have the potential to induce clinical benefits in patients. In this study, we compared the efficacy of six redox-active drugs, some already adopted in clinical trials, targeting NRF2 activation and frataxin expression in fibroblasts obtained from skin biopsies of FRDA patients. All of these drugs consistently increased NRF2 expression, but differential profiles of NRF2 downstream genes were activated. The Sulforaphane and N-acetylcysteine were particularly effective on genes involved in preventing inflammation and maintaining glutathione homeostasis, the dimethyl fumarate, omaxevolone, and EPI-743 in counteracting toxic products accumulation, the idebenone in mitochondrial protection. This study may contribute to develop synergic therapies, based on a combination of treatment molecules. MDPI 2019-10-21 /pmc/articles/PMC6829337/ /pubmed/31640150 http://dx.doi.org/10.3390/ijms20205211 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Petrillo, Sara
D’Amico, Jessica
La Rosa, Piergiorgio
Bertini, Enrico Silvio
Piemonte, Fiorella
Targeting NRF2 for the Treatment of Friedreich’s Ataxia: A Comparison among Drugs
title Targeting NRF2 for the Treatment of Friedreich’s Ataxia: A Comparison among Drugs
title_full Targeting NRF2 for the Treatment of Friedreich’s Ataxia: A Comparison among Drugs
title_fullStr Targeting NRF2 for the Treatment of Friedreich’s Ataxia: A Comparison among Drugs
title_full_unstemmed Targeting NRF2 for the Treatment of Friedreich’s Ataxia: A Comparison among Drugs
title_short Targeting NRF2 for the Treatment of Friedreich’s Ataxia: A Comparison among Drugs
title_sort targeting nrf2 for the treatment of friedreich’s ataxia: a comparison among drugs
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6829337/
https://www.ncbi.nlm.nih.gov/pubmed/31640150
http://dx.doi.org/10.3390/ijms20205211
work_keys_str_mv AT petrillosara targetingnrf2forthetreatmentoffriedreichsataxiaacomparisonamongdrugs
AT damicojessica targetingnrf2forthetreatmentoffriedreichsataxiaacomparisonamongdrugs
AT larosapiergiorgio targetingnrf2forthetreatmentoffriedreichsataxiaacomparisonamongdrugs
AT bertinienricosilvio targetingnrf2forthetreatmentoffriedreichsataxiaacomparisonamongdrugs
AT piemontefiorella targetingnrf2forthetreatmentoffriedreichsataxiaacomparisonamongdrugs